stimulating hormone (FSH) secretion induced by a single dose of the gonadotrophin-releasing hormone (GnRH) agonist 1 Department of Obstetrics/Gynecology and 2 Departments of (GnRHa) nafarelin with a markedly increased response of 17-Medicine and Pediatrics, University of Chicago, Pritzker School of hydroxyprogesterone (17-Prog) (Barnes et al., 1989; Ehrmann Medicine, Chicago, Illinois, USA et al., 1992). Responses of androstenedione (AD) and testoster-3 To whom correspondence should be addressed at: Advanced one (T) are also increased, but not to the same degree as 17- with a failure of suppression of free T by dexamethasone and methasone administration was followed by 5000 IU HCG is a reliable diagnostic test for FOH. This abnormality appears and blood samples for steroid hormone assay were obtained to result from a failure in the modulation of LH action within 0, 8, 16, and 24 h thereafter. Study subjects were normal thecal cells (Rosenfield et al., 1994) . women (n ϭ 13); women with functional ovarian hyper-
Prog. The 17-Prog response is similar to that seen in normal men, and the T response is intermediate between those of A controlled clinical study was designed to investigate the normal men and normal women. We have found that an value of human chorionic gonadotrophin (HCG) challenge exaggerated 17-Prog response to GnRHa correlates closely as a test for functional ovarian hyperandrogenism. Dexawith a failure of suppression of free T by dexamethasone and methasone administration was followed by 5000 IU HCG is a reliable diagnostic test for FOH. This abnormality appears and blood samples for steroid hormone assay were obtained to result from a failure in the modulation of LH action within 0, 8, 16, and 24 h thereafter. Study subjects were normal thecal cells (Rosenfield et al., 1994) .
women (n ϭ 13); women with functional ovarian hyper-
One might expect to demonstrate an exaggerated 17-Prog androgenism, defined by androgen excess, amenorrhoea response in FOH by stimulation with human chorionic and an increased 17-hydroxyprogesterone response to gonadotrophin (HCG), which is essentially an LH analogue nafarelin (n ϭ 6); and normal men (n ϭ 4). The responses of (Albert, 1969) . However, HCG has seldom been used as a test 17-hydroxyprogesterone, androstenedione and testosterone of ovarian androgenic function since Abraham et al. (1975) to HCG in women with functional ovarian hyperandrogenconcluded that 'the HCG stimulation test was of no practical ism were significantly greater than in normal women.
value in evaluating the source of excess androgens in hirsutism'. However, the 17-hydroxyprogesterone response to HCG In spite of our finding of a rise in urinary pregnanetriol, the in functional ovarian hyperandrogenism was significantly unique urinary metabolite of 17-Prog, significantly greater than lower after HCG than after nafarelin. The oestradiol normal, in hyperandrogenic anovulatory women (Rosenfield response was also significantly lower after HCG than et al., 1972) , the plasma 17-Prog responses to HCG were not nafarelin, although oestradiol concentration more than determined, nor, for that matter, were oestradiol responses. At doubled in normal women as well as in women with the time we considered that HCG test results could not be functional ovarian hyperandrogenism. The responses to interpreted without relating them to the coordinated function HCG confirm that functional ovarian hyperandrogenism abnormalities are luteinizing hormone (LH)-dependent.
of the specific follicle that secretes oestradiol and that this Therefore, the 17-hydroxyprogesterone response to HCG would not be possible. Having determined that GnRHa stimulacould represent a useful test for the diagnosis of ovarian tion provides a practical method to evaluate the combined hyperandrogenism. The lower 17-hydroxyprogesterone effect of LH and FSH on ovarian follicular function, it is response to HCG than to nafarelin in functional ovarian now, however, once again of interest to reevaluate the HCG hyperandrogenism suggests that a follicle-stimulating stimulation test for the diagnosis of ovarian hyperandrogenism. 15-18, 1995. nafarelin was greater than 7.8 nmol/l, 2 SD above the mean values in controls (Ehrmann et al., 1992 Response to HCG performed using previously published methods (Barnes et al., 1989;  The 17-Prog responses in men and FOH were not significantly Rosenfield et al., 1994) . Prolactin values were within the normal different after HCG ( Figure 1 ; Table I ). Baseline 17-Prog range. Basal gonadotrophin values have been published previously and 17-Prog responses to HCG were significantly greater in (Ehrmann et al., 1992) . All subjects received a pelvic examination normal men than normal women (P Ͻ 0.005 did not differ between stimulation tests (Table I) . However, reported (Ehrmann et al., 1992) using the unpaired t-test. In the there was a significant rise in the oestradiol to T ratio with FOH women and normal men, HCG and nafarelin test parameters both stimulation tests (HCG: 0.0039-0.0129; nafarelin:
were secondarily compared using the paired t-test. In situations 0.0077-0.0183; P Ͻ 0.05), suggesting that both tests resulted where data were not normally distributed, they were analysed after in an increase in aromatase activity.
logarithmic transformation.
HCG versus nafarelin tests
The findings resembled our previous observations in men, Results normal women, and FOH challenged with GnRHa without Women dexamethasone pretreatment (Barnes et al., 1989) . The 17-Baseline Prog responses in women and men were not significantly Baseline AD, T, and 17-Prog were higher in the FOH group different comparing HCG to nafarelin. The peak and compared to normal women (P Ͻ 0.01), while baseline incremental 17-Prog response in FOH was significantly plasma oestradiol concentrations were similar (Table I) . No lower after HCG compared to nafarelin (Figure 1 ; Table I ). significant differences in baseline steroids were present
The distribution of 17-Prog responses overlapped between between the HCG and nafarelin tests in either group.
FOH and normal women with HCG, but not nafarelin, testing. Baseline 17-Prog and 17-Prog responses to both Response to HCG HCG administration resulted in a peak steroid response HCG and nafarelin were significantly greater in normal men than normal women (P Ͻ 0.005), but neither differed between 16 and 24 h, as also occurs with nafarelin ( Figure  1 ). The peak 17-Prog response to HCG was significantly significantly compared to FOH. In FOH the total androgen response, AD plus T, was intermediate between normal higher in FOH (P Ͻ 0.01) than in normal women, as was the incremental rise (P Ͻ 0.01; Figure 2 ; Table I ). Although women and men after both HCG and nafarelin. Baseline and peak AD and T were significantly greater in men than the 17-Prog response was significantly greater in FOH than in normal women, there was an overlap in the distribution in both groups of women after either HCG or nafarelin (P Ͻ 0.05). Baseline and peak oestradiol during HCG testing, of 17-Prog responses between FOH and normal women after HCG testing that did not occur with the nafarelin test and the oestradiol peak and incremental rise upon nafarelin testing were significantly higher (P Ͻ 0.05) in FOH than as shown in Figure 2 . In FOH, both peak and incremental men. Baseline oestradiol before HCG and nafarelin testing was significantly higher in normal women than men (P Ͻ 0.04). Peak oestradiol and oestradiol incremental rise were significantly greater in normal women than men after nafarelin (P Ͻ 0.01) but not after HCG. In normal women, the peak and incremental oestradiol responses were significantly lower after HCG than after nafarelin stimulation (Table I) . The peak oestradiol/T ratio was significantly lower after HCG than nafarelin in FOH (0.28 Ϯ 0.05 versus 0.72 Ϯ 12; P Ͻ 0.01) and also tended to be so in normal women (2.49 Ϯ 0.98 versus 6.65 Ϯ 2.88). The peak androgen to 17-Prog ratio was significantly higher after HCG than nafarelin in FOH (2.06 Ϯ 0.37 versus 1.21 Ϯ 0.16; P Ͻ 0.03), but not in normal women (1.53 Ϯ 0.25 versus 1.16 Ϯ 0.08).
Discussion
These studies demonstrate abnormalities of 17-Prog and androgen secretion in response to HCG in FOH which are similar in many ways to those after GnRHa administration and which, therefore, indicate that these abnormalities are LHdependent. 17-Prog rose two-fold more than AD or T in response to HCG stimulation. The response of all these steroids is significantly greater in FOH than in normal women, and the magnitude of the androgen responses to HCG is similar to that in response to nafarelin. However, in FOH the peak and absolute rise in 17-Prog were significantly lower after HCG than after nafarelin. If suggest the superiority of one test over the other. Physiologicnormal women (n ϭ13 for HCG and n ϭ 17 for nafarelin; Ehrmann et al., 1992) and men (n ϭ 4).
ally it would imply that FSH plays a role in modulating they and the oestradiol/T ratio were less than half of that in response to nafarelin. Considerable data indicate that human thecal cells are capable of forming oestradiol throughout the life span of the antral follicle (Ryan and Petro, 1966; Channing, 1969; McNatty et al., 1979a; GillingSmith et al., 1994) . Additional data indicate that this oestradiol synthesis is under LH control rather than FSH control (McNatty et al., 1979b; Gilling-Smith et al., 1994) . The only evidence that human thecal cells cannot form oestradiol was obtained in short-term cultures in the absence of supplemental serum (Moon et al., 1978; Tsang et al., 1980) , which is compatible with a dependency of aromatase activity upon growth factors similar to that shown for other steroidogenic steps (Adashi et al., 1985; Ehrmann et al., 1995) . The molecular confirmation of thecal localization of aromatase activity is unsettled. Thecal immunostaining for cytochrome P450 aromatase has been variously reported as strong (Inkster and Brodie, 1991) , inconsistent (Suzuki et al., 1993) or non-existent (Tamura et al., 1992) . A conclusion that the oestradiol rise after HCG is due to thecal cell aromatase activity should, however, be reached with caution. Oestrogen secretion in vitro by thecal cells from normal and polycystic ovaries is considerably lower than that by granulosa cells (McNatty et al., 1979a,b; Hillier et al., 1981) . An alternate explanation for these findings could be that androgens exert a rapid paracrine effect on granulosa cells, upregulating their aromatase activity (Haning et al., secretory abnormalities in FOH are LH-dependent and suggest that HCG may be useful as a diagnostic test for FOH. Whether HCG testing will have the same diagnostic efficiency as GnRHa stimulation remains to be determined. the steroidogenic response to LH. This possibility is
The greater 17-Prog response to GnRHa than to HCG is supported by in-vitro data which indicate that the 17-Prog consistent with the hypothesis that an FSH responsive factor response to LH of isolated theca cells in culture from exerts a modulating effect on thecal 17-Prog secretion. polycystic ovaries is no more abnormal than is that of AD Furthermore, our data are consistent with in-vitro evidence (Gilling-Smith et al., 1994) . In addition, our in-vivo data that thecal cells secrete oestrogen in response to LH in show an apparent dose-response relationship of 17-Prog to addition to their well-established indirect effect of supplying LH that is much steeper in FOH than in normal women androgens as substrates for oestradiol formation. With further during nafarelin testing (Rosenfield et al., 1994) . Studies in investigation it may become necessary to modify the standard rats have shown that thecal cells exposed in vivo to FSH 2-gonadotrophin, 2-cell model of ovarian steroid production have five-fold more P450c17 mRNA and two-fold greater to include the lack of rigid compartmentalization of oestrogen androgen production in response to LH in vitro than synthesis and to include paracrine regulation of thecal do unexposed cells (Smyth et al., 1993) . Furthermore, androgen production (Channing, 1969; Suzuki et al., 1993) . hyperandrogenism does not seem to occur when LH excess Dose-response studies utilizing recombinant FSH and LH occurs in the presence of an inactive FSH (Matthews et al., should further delineate the FSH responsive factor effect on 1993). These results are compatible with an FSH responsive 17-Prog secretion in FOH. factor modulating the steroidogenic response to LH in FOH.
The striking oestradiol response to HCG in both normal and FOH women was not anticipated from the 2-cell, 2
